What is Wedbush’s Estimate for ZNTL Q1 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Wedbush issued their Q1 2026 EPS estimates for Zentalis Pharmaceuticals in a note issued to investors on Tuesday, November 11th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.32) per share for the quarter. Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS and Q4 2026 earnings at ($0.33) EPS.

ZNTL has been the topic of several other reports. HC Wainwright upgraded Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Leerink Partners reissued a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Finally, Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.03.

Zentalis Pharmaceuticals Stock Down 1.5%

ZNTL stock opened at $1.32 on Wednesday. The stock has a market capitalization of $95.37 million, a price-to-earnings ratio of -0.64 and a beta of 1.87. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $4.16. The stock’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $1.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC grew its stake in Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after buying an additional 7,579 shares during the period. Catalyst Funds Management Pty Ltd purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth $31,000. Alpine Global Management LLC acquired a new stake in Zentalis Pharmaceuticals in the 1st quarter valued at $48,000. SG Americas Securities LLC raised its position in Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after purchasing an additional 8,236 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in Zentalis Pharmaceuticals in the second quarter valued at about $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.